Literature DB >> 25500981

Markers of early atherosclerosis, oxidative stress and inflammation in patients with acromegaly.

Cigdem Ozkan1, Alev Eroglu Altinova, Ethem Turgay Cerit, Cagri Yayla, Asife Sahinarslan, Duygu Sahin, Aylin Sepici Dincel, Fusun Balos Toruner, Mujde Akturk, Metin Arslan.   

Abstract

PURPOSE: Data regarding atherosclerosis in acromegaly is controversial in literature. We aimed to investigate the markers of early atherosclerosis, oxidative stress, inflammation and their relationships with each other in acromegaly.
METHODS: Thirty-nine patients with acromegaly and 40 control subjects were enrolled. Patients were classified into two groups; active acromegaly (AA) and controlled acromegaly (CA). Controls were matched by age, gender, body mass index and presence of cardiovascular risk factors. Flow mediated dilatation (FMD), carotid intima media thickness (CIMT), epicardial adipose tissue thickness (EAT) were measured and serum levels of oxidative stress parameters, high mobility group box 1 protein (HMGB1) and high sensitive CRP (hs CRP) were evaluated.
RESULTS: Significantly decreased FMD, increased CIMT and EAT were found in patients with acromegaly compared to controls (p < 0.01, p < 0.05, p < 0.001, respectively). EAT correlated negatively with FMD (r = -0.24, p = 0.038) and positively with CIMT (r = 0.37, p < 0.01). Presence of acromegaly, hypertension and age were found to be the predictors of early atherosclerosis (p < 0.05). Hs CRP was decreased in AA compared to controls (p = 0.01). There were no significant differences for HMGB1 and oxidized LDL (ox-LDL) cholesterol levels and total antioxidant capacity (TAC) between AA, CA and controls (p > 0.05).
CONCLUSION: Early atherosclerosis measured with FMD, CIMT and EAT may exist in acromegaly. However, decreased hs CRP and unchanged HMGB1, ox-LDL and TAC levels suggest that inflammation and oxidative stress do not seem to contribute to the development of atherosclerosis in these patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25500981     DOI: 10.1007/s11102-014-0621-6

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  47 in total

Review 1.  Epicardial fat: from the biomolecular aspects to the clinical practice.

Authors:  Gianluca Iacobellis; Alexis E Malavazos; Massimiliano M Corsi
Journal:  Int J Biochem Cell Biol       Date:  2011-09-28       Impact factor: 5.085

2.  The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues.

Authors:  M C De Martino; R S Auriemma; G Brevetti; G Vitale; V Schiano; M Galdiero; L Grasso; G Lombardi; A Colao; R Pivonello
Journal:  J Endocrinol Invest       Date:  2010-07-01       Impact factor: 4.256

3.  Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk.

Authors:  Carlos Reyes-Vidal; Jean Carlos Fernandez; Jeffrey N Bruce; Celina Crisman; Irene M Conwell; Jane Kostadinov; Eliza B Geer; Kalmon D Post; Pamela U Freda
Journal:  J Clin Endocrinol Metab       Date:  2014-08-19       Impact factor: 5.958

4.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

5.  Acromegaly per se does not increase the risk for coronary artery disease.

Authors:  Hiroyoshi Akutsu; Jürgen Kreutzer; Gerald Wasmeier; Dieter Ropers; Christian Rost; Matthias Möhlig; Henri Wallaschofski; Michael Buchfelder; Christof Schöfl
Journal:  Eur J Endocrinol       Date:  2010-02-09       Impact factor: 6.664

6.  Early vascular alterations in acromegaly.

Authors:  Gregorio Brevetti; Paolo Marzullo; Antonio Silvestro; Rosario Pivonello; Gabriella Oliva; Carolina di Somma; Gaetano Lombardi; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2002-07       Impact factor: 5.958

7.  Investigation of early atherosclerotic changes in acromegalic patients.

Authors:  I Kartal; H Oflaz; B Pamukçu; M Meriç; F Aral; N Ozbey; F Alagöl
Journal:  Int J Clin Pract       Date:  2008-04-16       Impact factor: 2.503

8.  Alterations in biomarkers of cardiovascular disease (CVD) in active acromegaly.

Authors:  L Boero; M Manavela; L Gómez Rosso; C Insua; V Berardi; M C Fornari; F Brites
Journal:  Clin Endocrinol (Oxf)       Date:  2009-01       Impact factor: 3.478

9.  Three noninvasive methods in the evaluation of subclinical cardiovascular disease in patients with acromegaly: epicardial fat thickness, aortic stiffness and serum cell adhesion molecules.

Authors:  Oya Topaloglu; Muyesser Sayki Arslan; Osman Turak; Zeynep Ginis; Mustafa Sahin; Muhammet Cebeci; Bekir Ucan; Evrim Cakir; Basak Karbek; Mustafa Ozbek; Erman Cakal; Tuncay Delibasi
Journal:  Clin Endocrinol (Oxf)       Date:  2013-12-12       Impact factor: 3.478

10.  Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels: insights from the Belgian registry of acromegaly.

Authors:  Johan Verhelst; Brigitte Velkeniers; Dominique Maiter; Patrick Haentjens; Guy T'Sjoen; Ernst Rietzschel; Bernard Corvilain; Pascale Abrams; Frank Nobels; Roger Abs; Marie Bex
Journal:  Eur J Endocrinol       Date:  2013-01-17       Impact factor: 6.664

View more
  12 in total

1.  Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.

Authors:  Claire Briet; Mirela Diana Ilie; Emmanuelle Kuhn; Luigi Maione; Sylvie Brailly-Tabard; Sylvie Salenave; Bertrand Cariou; Philippe Chanson
Journal:  Endocrine       Date:  2018-11-05       Impact factor: 3.633

2.  The effect of disease control on mean platelet volume and red blood cell distribution in patients with acromegaly.

Authors:  Rifki Ucler; Mehmet Aslan; Murat Atmaca; Murat Alay; Esra Nur Ademoglu; Zehra Candan; Ismail Gulsen
Journal:  Int J Clin Exp Med       Date:  2015-04-15

3.  Serum paraoxonase level and paraoxonase polymorphism in patients with acromegaly.

Authors:  Dilek Arpaci; Sevim Karakas Celik; Murat Can; Esra Ermiş; Fatih Kuzu; Furuzan Kokturk; Ayse Ceylan Hamamcioglu; Ahmet Dursun; Taner Bayraktaroglu
Journal:  Redox Rep       Date:  2016-02-15       Impact factor: 4.412

4.  High chitotriosidase and AGE levels in acromegaly: a case-control study.

Authors:  Hatice Ozisik; Banu Sarer Yurekli; Aslı Suner; Oznur Copur; Eser Yıldırım Sozmen; Suha Sureyya Ozbek; Ahmet Kasım Karabulut; Ilgın Yıldırım Simsir; Mehmet Erdogan; Sevki Cetinkalp; Fusun Saygili
Journal:  Hormones (Athens)       Date:  2022-10-15       Impact factor: 3.419

5.  ENDOTHELIAL DYSFUNCTION IN ACROMEGALIC PATIENTS: A CASE-CONTROL STUDY.

Authors:  S Ghiorghe; A Dragomir; D Bartos
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Jul-Sep       Impact factor: 0.877

Review 6.  Growth Hormone and Aging: New Findings.

Authors:  Andrzej Bartke; Erin Hascup; Kevin Hascup; Michal M Masternak
Journal:  World J Mens Health       Date:  2021-02-03       Impact factor: 5.400

Review 7.  The Endothelium in Acromegaly.

Authors:  Pietro Maffei; Francesca Dassie; Alexandra Wennberg; Matteo Parolin; Roberto Vettor
Journal:  Front Endocrinol (Lausanne)       Date:  2019-07-24       Impact factor: 5.555

Review 8.  Acromegaly, inflammation and cardiovascular disease: a review.

Authors:  Thalijn L C Wolters; Mihai G Netea; Niels P Riksen; Adrianus R M M Hermus; Romana T Netea-Maier
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

9.  Fasting levels of growth hormone are associated with carotid intima media thickness but are not affected by fluvastatin treatment.

Authors:  Erik Hallengren; Peter Almgren; Maria Rosvall; Gerd Östling; Margaretha Persson; Andreas Bergmann; Joachim Struck; Gunnar Engström; Bo Hedblad; Olle Melander
Journal:  BMC Cardiovasc Disord       Date:  2017-05-16       Impact factor: 2.298

10.  The metabonomics study of P-selectin glycoprotein ligand-1 (PSGL-1) deficiency inhibiting the progression of atherosclerosis in LDLR-/- mice.

Authors:  Binglin Li; Xin Lu; Jia Wang; Xiaodong He; Quliang Gu; Lijing Wang; Yongxia Yang
Journal:  Int J Biol Sci       Date:  2018-01-01       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.